A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in
patients aged 6-12 years with ADHD in a laboratory classroom setting. This study has a 6-week
open-label treatment optimization period followed by a one week randomized, double-blind,
placebo-controlled test phase.